- Who We Are
- Our Focus
- Clinical Programs
Solving persistent challenges in treating serious inflammatory skin diseases
Dermatological diseases affect tens of millions of people worldwide each year, impacting their physical, functional and emotional well-being. Yet, current standards of care to treat many serious skin diseases are outdated, having remained unchanged for decades, and carry significant treatment limitations, resulting in poor outcomes that can have a negative impact on patient quality of life.
Physicians seek simpler and more effective solutions to address the persistent treatment challenges of immune-mediated dermatological diseases and conditions, where patients typically must settle for trade-offs in drug efficacy, safety and tolerability. Today, 90% or more of patients with plaque psoriasis and other inflammatory dermatological conditions are treated with topical therapies, often with multiple prescriptions to manage the disparate locations of the disease and the limitations of each therapy. Yet, there have been no FDA approvals for a topical psoriasis therapy with a novel mechanism of action in over 20 years. While biologics have revolutionized the treatment of moderate-to-severe psoriasis, their use is limited to only 6% of patients.
Arcutis is stepping in to fill the innovation gap in the dermatology space. The company is leveraging its deep dermatology expertise and the latest advances in immunology and inflammation to develop best-in-class products that have the potential to eliminate the treatment compromises dermatologists and patients are forced to make in managing their plaque psoriasis, atopic dermatitis, seborrheic dermatitis and other conditions, and to elevate the standard of patient care.